Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | CTSG | P08311 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 2/20 | 0.40 |
| ▸ | FAP | Q12884 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | XIAP | P98170 | 2/20 | 0.38 |
| ▸ | CMA1 | P23946 | 11/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6276559 | 0.93 | ELANE (0.44) | ELANECTSGDPP4DPP8DPP9 | |
| SCHEMBL4457003 | 0.92 | ELANE (0.46) | ELANECTSGCMA1 | |
| SCHEMBL4463484 | 0.91 | ELANE (0.53) | ELANECTSGCMA1 | |
| SCHEMBL6285044 | 0.81 | ELANE (0.42) | ELANECTSGDPP4DPP8DPP9 | |
| SCHEMBL6279789 | 0.78 | ELANE (0.53) | ELANECTSGCMA1 | |
| SCHEMBL6276132 | 0.75 | ELANE (0.57) | ELANECTSGCMA1 | |
| SCHEMBL5969313 | 0.70 | ELANE (0.63) | ELANECTSGCMA1 | |
| SCHEMBL5552336 | 0.67 | CTSL (0.54) | DPP4DPP8DPP9CMA1F10 | |
| SCHEMBL6678314 | 0.66 | ELANE (0.47) | ELANECTSGCMA1 | |
| SCHEMBL6803099 | 0.65 | ELANE (0.44) | ELANECTSGCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852744-B2 | Pyrrolidine derivatives and their use as chymase inhibitor | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2005-02-08 | — | — | US | claimed |
| US-20040102384-A1 | Pyrrolidine derivatives and their use as chymase inhibitor | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-05-27 | — | — | US | claimed |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | MICROBIA, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-6852744-B2 | Pyrrolidine derivatives and their use as chymase inhibitor | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2005-02-08 | — | — | US | disclosed |
| US-20040102384-A1 | Pyrrolidine derivatives and their use as chymase inhibitor | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102384-A1 | Pyrrolidine derivatives and their use as chymase inhibitor | CMA1, CTRL, TPSD1 | ELANE 634/4885CTSG 71/4885PREP 7/4885 |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | PTGIS, PTGIR, GRPR | ELANE 2176/4885CTSG 1249/4885PREP 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.